Canada’s non-profit advocacy organisation TheraPsil has announced the launch of its MDMA-assisted psychotherapy training programme.
MDMA and psilocybin were recently added to Canada’s Special Access Programme, to give patients access to these therapies in select and authorised circumstances.
To ensure there are enough therapists trained to deliver these treatments, TheraPsil has launched an MDMA-assisted therapy training programme.
The organisation has said that it now has over 500 trained healthcare professionals in its Fundamentals of Psilocybin-Assisted Psychotherapy training programmes.
The development of the training programme’s curriculum and rollout of the programme will be under the leadership of Dr Ingrid Pacey, a distinguished TheraPsil trainer who served as the Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver.
Pacey commented: “Psychotherapists need to be trained to work with a wide variety of psychedelics to best serve the needs of their prospective patients.”
TheraPsil has stated it is now embarking on a new chapter of growth and innovation, enriching its mission to deliver safe, efficacious therapies for those grappling with mental health challenges and that the programme expansion extends TheraPsil’s advocacy efforts to include not only psilocybin but also MDMA, through the Special Access Program (SAP) for patients in medical need.
Yasmeen deRosenroll, TheraPsil’s Director of Training and Operations, added: “We are thrilled to unveil the expansion of our training programs, designed to offer comprehensive support to our valued stakeholders.
“Our organisation is deeply dedicated to achieving clinical excellence while embracing a patient-centered philosophy. We are excited to extend our support to a wider array of trauma survivors, enhancing access to legal MDMA-Assisted Psychotherapy through Health Canada’s SAP program, and steadfastly addressing the diverse needs of the patients we serve.”
TheraPsil has said that the pilot phase of the training is expected to launch in early 2024 and will cater to practitioners who have successfully completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training programme.
To find out more please click here.
